Posted by Michael Wonder on 17 Oct 2025
Rare cancer lifeline comes with dual drug discounts
17 October 2025 - Two common immunotherapy drugs will now be subsidised for all advanced or metastatic cancers, providing a lifeline to patients with some of the rarest conditions.
The PBAC called for the drugs nivolumab and ipilimumab — sold as Opdivo and Yervoy, respectively — to be bankrolled by the government and listed on the PBS. It will allow patients access to each at $31.60 per prescription.
